ATA3219
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ATA3219, covering 2025-04-24 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]